Paris, France

Time filter

Source Type

Patent
Danone Inc. and French National Institute for Agricultural Research | Date: 2015-04-15

The present invention provides the use of Lactobacillus rhamnosus, for maintaining or increasing the intestinal microbiota diversity in a subject.


Patent
Danone Inc. and French National Institute for Agricultural Research | Date: 2015-04-15

The present invention provides the use of Lactobacillus paracasei, for maintaining or increasing the intestinal microbiota diversity in a subject having dysbiosis.


Patent
Danone Inc. and French National Institute for Agricultural Research | Date: 2017-02-22

The present invention provides the use of Lactobacillus rhamnosus, for maintaining or increasing the intestinal microbiota diversity in a subject.


Patent
Compagnie Gervais Danone | Date: 2016-10-06

The present invention discloses strains of Lactobacillus and Streptococcus which have a capacity to degrade gliadin peptides involved in coeliac disease and which peptide degrading activity is stable under low pH and in the presence of mammalian digestive enzymes. These strains are suitable in a product for use in prevention and/or treatment of celiac disease.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: HEALTH.2012.2.1.2-2 | Award Amount: 23.12M | Year: 2012

METACARDIS applies a systems medicine multilevel approach to identify biological relationships between gut microbiota, assessed by metagenomics, and host genome expression regulation, which will improve understanding and innovative care of cardiometabolic diseases (CMD) and their comorbidities. CMD comprise metabolic (obesity, diabetes) and heart diseases characterized by a chronic evolution in ageing populations and costly treatments. Therapies require novel integrated approaches taking into account CMD natural evolution. METACARDIS associates European leaders in metagenomics, who have been successful in establishing the structure of the human microbiome as part of the EU FP7 MetaHIT consortium, clinical and fundamental researchers, SME, patients associations and food companies to improve the understanding of pathophysiological mechanisms, prognosis and diagnosis of CMD. We will use next-generation sequencing technologies and high throughput metabolomic platforms to identify gut microbiota- and metabolomic-derived biomarkers and targets associated with CMD risks. The pathophysiological role of these markers will be tested in both preclinical models and replication cohorts allowing the study of CMD progression in patients collected in three European clinical centres of excellence. Their impact on host gene transcription will be characterised in patients selected for typical features of CMD evolution. Application of computational models and visualisation tools to complex datasets combining clinical information, environmental patterns and gut microbiome, metabolome and transcriptome data is a central integrating component in the research, which will be driven by world leaders in metagenomic and functional genomic data analysis. These studies will identify novel molecular targets, biomarkers and predictors of CMD progression, paving the way for personalized medicine in CMD.


Grant
Agency: European Commission | Branch: H2020 | Program: IA | Phase: ICT-12-2016 | Award Amount: 6.76M | Year: 2016

IMPACT GROWTH will fund 4 European Superstar Startups (unicorn potential) confirmed by top VC investors and global corporates of 4 smart verticals: cities, digital content, agrifood and factories 48 companies exploiting Future Internet research results will be discovered out of a deal flow of 5.000 startups through 4 OpenCalls. They will join an acceleration programme and will start a crowdfunding track. A live due diligence from the acceleration and the market response through the crowd will select the best companies. 4 out of the 48 startups will succeed in reaching the 1.5 million euros crowd funded investment led by the VCs and platforms in the consortium leveraging the 6 million euros of public funding with 6 additional million euros of private investment. The IMPACT GROWTH consortium includes: Mobile World Congress as the reference digital mobile event in the planet; 4 corporates including Danone, Ferrovial, NTT DOCOMO BuonGiorno and MADE (integrates LEGO and Vestas among others); FIWARE Foundation to guarantee the proper exploitation of research results aligning them with other FIWARE initiatives; Accelerace and Kibo Ventures as top VCs; ISDI as leading FIWARE accelerator; FundingBox as leading European startups funding platform; INVESDOR as first global crowdfunded platform with MiFID license and ISDI Mexico that will reinforce EC objectives of globalizing the Future Internet efforts via Mexico and as a pilot on how to engage with Plug & Play and Tel Aviv Go Global joining the project via LoI; PARP, the agency for startups in Poland, will support the consortium via LoI to pilot the adoption of best practices for ESIF purposes under Smart Specialization Strategies for regions. IMPACT GROWTH will help demonstrate that public funded research results with a continuity approach (continued support from seed to initial series round) can help top startups become European Superstars and can turn the EU into the EU of entrepreneurial states.


The invention relates to the use of lactic acid bacteria, for use in modifying the enteric nervous system and more particularly in treating and/or preventing intestinal disorders such as constipation and/or irritable bowel disease.


Patent
Danone Inc. | Date: 2016-06-15

The present invention relates to food-grade bacteria strain being capable of removing mercury from an aqueous environment.


Patent
Clariant and Danone Inc. | Date: 2016-03-16

The invention relates to an article comprising a monolayer or multilayer thermoplastic material, said material comprises(i) 38.00 to 99.95 %, preferably 67.00 to 99.9 %, more preferably 57.00 to 99.85 %, by weight of polylactic acid,(ii) 0.05 to 4.90 %, preferably 0.10 to 2.90 %, more preferably 0.15 to 2.00 %, even more preferably 0.2 to 1.00 %, most preferably 0.25 to 0.75 %, by weight of an epoxidized vegetable oil;(iii) 0 to 60.00 %, preferably 0 to 40.00 %, more preferably 0 to 30.00 %, by weight of further additives selected from the group consisting of impact modifiers, plasticisers, crosslinking agents, foaming agents, fillers, colorants, stabilizers, lubricants, and mixtures thereof,the weight percentages being relative to total weight of the monolayer or multilayer thermoplastic material and adding up to 100 %.


Perrier E.,Danone Inc.
The British journal of nutrition | Year: 2013

Little is known about the impact of habitual fluid intake on physiology. Specifically, biomarkers of hydration status and body water regulation have not been adequately explored in adults who consume different fluid volumes in everyday conditions, without prolonged exercise or environmental exposure. The purpose of the present study was to compare adults with habitually different fluid intakes with respect to biomarkers implicated in the assessment of hydration status, the regulation of total body water and the risk of kidney pathologies. In the present cross-sectional study, seventy-one adults (thirty-two men, thirty-nine women, age 25-40 years) were classified according to daily fluid intake: thirty-nine low drinkers (LD; ≤ 1·2 litres/d) and thirty-two high drinkers (HD; 2-4 litres/d). During four consecutive days, urinary parameters (first morning urine (FMU) on day 1 and subsequent 24 h urine (24hU) collections), blood parameters, and food and beverage intake were assessed. ANOVA and non-parametric comparisons revealed significant differences between the LD and HD groups in 24hU volume (1·0 (se 0·1) v. 2·4 (se 0·1) litres), specific gravity (median 1·023 v. 1·010), osmolality (767 (se 27) v. 371 (se 33) mOsm/kg) and colour (3·1 (se 0·2) v. 1·8 (se 0·2)). Similarly, in the FMU, the LD group produced a smaller amount of more concentrated urine. Plasma cortisol, creatinine and arginine vasopressin concentrations were significantly higher among the LD. Plasma osmolality was similar between the groups, suggesting physiological adaptations to preserve plasma osmolality despite low fluid intake. The long-term impact of adaptations to preserve plasma osmolality must be examined, particularly in the context of renal health.

Loading Danone Inc. collaborators
Loading Danone Inc. collaborators